The Asia Pacific enteral and parenteral medical nutrition market is expected to grow from US$ 2,339.32 million in 2023 to US$ 3,352.69 million by 2028. It is estimated to grow at a CAGR of 7.5% from 2023 to 2028.
Growing Strategic Initiatives by Companies Fuels Asia Pacific Enteral and Parenteral Medical Nutrition Market
Companies operating in the enteral and parenteral medical nutrition market constantly focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a greater than existing customer base. A few of the noteworthy developments in the enteral and parenteral medical nutrition market are mentioned such as- In June 2022, Nestle Health Science acquired The Better Health Company (TBHC) from CDH Investments and TBHC founding shareholders. The acquisition includes the GO Healthy brand, along with its vitamin and supplement lineups; the Manuka honey brand Egmont; and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins, minerals, and supplements. The acquisition helped Nestle Health Science strengthen and expand its presence in New Zealand, Australia, and other Asia Pacific countries. In September 2021, Abbott introduced plant-based protein and organic food ingredients—PediaSure Harvest and Ensure Harvest—for people relying on feeding tubes. Harvest products can be used as sole-source nutrition or a supplement to satisfy daily nutrition requirements. In December 2020, Abbott launched the Pedialyte Hydration Solution, a new formulation designed with key nutrients to support immune health. Pedialyte with immune support includes prebiotics, vitamin B12, vitamin C, vitamin E, and zinc, specifically chosen for their importance in the development and improvement of the immune system. In October 2020, Nutricia (part of Danone) acquired Real Food Blends. The company helps contribute to the real food blends mission and portfolio by bringing more unique and nutritious choices to children and adults dependent on feeding tubes. Therefore, introducing products such as ready-to-drink and ready-to-use nutritional supplements; the development of innovative products targeting various health issues; and strategic moves such as expansions and acquisitions allow companies in the enteral and parenteral medical nutrition market to create new or improved products and new business to remain competitive in the market. Thus, such strategic growth initiatives create significant growth opportunities in the market.
Asia Pacific Enteral and Parenteral Medical Nutrition Market Overview
Asia Pacific (APAC) is the fastest-growing regional market for enteral and parenteral medical nutrition and is segmented into China, Japan, India, South Korea, Australia, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. Factors contributing to the growth of the market in the region are the rising prevalence of chronic diseases and the growing presence of market players across the region, conferring the highest manufacturing of enteral & parenteral nutrition products. Furthermore, supportive government initiatives and research in the field of nutrition boost market growth.
Asia Pacific Enteral and Parenteral Medical Nutrition Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Enteral and Parenteral Medical Nutrition Market Segmentation
The Asia Pacific enteral and parenteral medical nutrition market is segmented into indication, nutrition type, form, product type, route of administration, age group, and distribution channel, and country.
Based on indication, the Asia Pacific enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023. Gastrointestinal disorders are segmented into IBD, IBS, and others.
Based on nutrition type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held a larger share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on form, the Asia Pacific enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on product type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on route of administration, the Asia Pacific enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on age group, the Asia Pacific enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on distribution channel, the Asia Pacific enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023
Based on country, the Asia Pacific enteral and parenteral medical nutrition market is segmented into China, Japan, India, Australia, South Korea, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. China dominated the share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Abbott Laboratories; B. Braun SE; Baxter International Inc; Fresenius Kabi AG; Nestle SA; and Nutricia International BV are the leading companies operating in the Asia Pacific enteral and parenteral medical nutrition market.
Asia Pacific Enteral and Parenteral Medical Nutrition Market Strategic Insights
Asia Pacific Enteral and Parenteral Medical NutritionMarket Report Highlights
| Report Attribute | Details |
| Market size in 2023 | US$ 2,339.32 Million |
| Market Size by 2028 | US$ 3,352.69 Million |
| CAGR (2023 - 2028) | 7.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Indication
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
Asia Pacific Enteral and Parenteral Medical Nutrition Market Country and Regional Insights
